Saltar al contenido principal

DNB Fund Health Care

Clase de acciones

Invierte en un sector con estabilidad, innovación y relevancia global.

La salud es uno de los sectores más estables y críticos para la sociedad en la economía mundial. La demanda está impulsada por necesidades fundamentales, independientemente de los ciclos económicos, y cada vez más inversores ven el valor de una exposición a largo plazo en el sector. DNB Health Care proporciona acceso a un amplio y global universo de empresas que desarrollan soluciones para servicios de salud mejores, más eficientes y más accesibles.

Las empresas en el fondo operan en un sector impulsado por megatendencias estructurales como el envejecimiento de la población, el aumento de enfermedades relacionadas con el estilo de vida y la creciente priorización política de las inversiones en salud. El fondo invierte en áreas establecidas y emergentes dentro de fármacos, biotecnología, dispositivos médicos y servicios de salud, con un claro enfoque en la innovación y las necesidades de tratamiento futuro. Al mismo tiempo, nuevas tecnologías, como la inteligencia artificial y la automatización, se están adoptando rápidamente en la investigación, el desarrollo y el tratamiento de pacientes, lo que ofrece atractivas oportunidades de crecimiento y potencial para la creación de valor en diferentes entornos de mercado.

El fondo de acciones gestionado activamente invierte típicamente en 30–50 empresas a través de los subsegmentos del sector salud. El fondo busca empresas con buenas perspectivas de crecimiento, y una valuación y perfil de riesgo atractivos.

El proceso de inversión está estructurado y fundamentado, con un enfoque claro en la valuación y la gestión del riesgo. Los gestores identifican empresas de calidad con ventajas competitivas sostenibles y creación de valor a largo plazo, e incluyen también inversiones selectivas en empresas biotecnológicas medianas basadas en la propia experiencia sectorial de DNB.

Áreas principales de inversión: Fármacos, biotecnología, tecnología y servicios de investigación, diagnóstico, dispositivos médicos, servicios de salud e infraestructura, seguros de salud, servicios de salud digitales.

Por qué invertir en este fondo

Videos relacionados

Introducción de fondos por el gestor de cartera Rune Sand

DNB Fund Health Care A (ACC) EUR

Votación

One way to positively influence companies is through voting at general meetings. Our voting guidelines require us to vote at all general meetings of all Norwegian companies in which we have investments. We have chosen a systematic approach to determining which international companies' general meetings we will vote at.

Normas y estándares internacionales

ESG data is integrated into our portfolio management system and is used to assess risks and opportunities related to ESG in investment decisions.

DNB Fund Health Care A (ACC) EUR

Información legal

This document constitutes a marketing communication. Investors should read the prospectus, Key Information Document (KID), semiannual and annual reports, and summary of investor rights before making any investment decision. English versions are available at www.dnbam.com under “Our Funds”, at DNB Asset Management AS, Dronning Eufemias gate 30, 0021 Oslo, Norway, or at the management company FundPartner Solutions (Europe) S.A., 15, avenue John F. Kennedy, L-1855 Luxembourg. Local language versions may also be available. Not all funds or fund units are available for sale in all countries. This material is not directed to, nor intended for use by, any person or entity in a jurisdiction where distribution would be unlawful. Tax treatment depends on individual circumstances and may change over time. References to rankings, ratings, or awards are not guarantees of future performance. Investments in funds carry financial risk. Note: Investing in the Fund involves acquiring units or shares of the Fund, not the underlying holdings. Issuer: DNB Asset Management AS, authorised and regulated by Finanstilsynet, Norway, and part of DNB Group. Switzerland: Representative: FundPartner Solutions (Switzerland) S.A., Route des Acacias 60, CH-1211 Geneva 73. Paying Agent: Banque Pictet & Cie SA, Route des Acacias 60, CH-1211 Geneva 73. USA: Fund units may not be offered, sold, or transferred in the United States. UK: This document constitutes a financial promotion under Section 21 of the UK Financial Services and Markets Act 2000 (as amended) and was approved by Carne International Financial Services (UK) Limited, authorised and regulated by the FCA. UK investors cannot refer complaints against the Management Company or Depositary to the UK Financial Ombudsman Service, nor are losses covered by the Financial Services Compensation Scheme. Complaints may be made to the SICAV, Management Company, or Operator/Depositary via the CSSF if the CSSF’s conditions for out-of-court complaints are met. UK investors may contact DNB Bank ASA for guidance on complaints or alternative dispute resolution. Investor Rights Summary (English): DNB SICAV (LU-Funds): https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf.coredownload.pdf No part of this material may be copied or redistributed without prior written consent from DNB Asset Management AS.

Indicador de sostenibilidad

The fund promotes, in addition to other considerations, environmental and social aspects through its investment strategy.

This equity fund aims to maximise the return on the fund's investments over the long term, without taking undue risk. The fund invests in equities of companies in healthcare, pharmaceuticals, medical devices, biotechnology and related sectors, listed on exchanges and regulated markets worldwide. The fund is actively managed. Investment decisions are based on long-term fundamental analysis, involving thorough assessment of companies, markets and other market factors that may affect companies' performance.

Diálogos

We engage in dialogue with companies. The dialogue can address specific ESG issues (reactive dialogue), or more generally help influence companies in a more sustainable direction (proactive dialogue). The detailed Responsible Investment Policy and the Corporate Exclusion List are available at: https://dnbam.com/en/responsible-investments/esg-overview-dnb-funds

Establecimiento de estándares

Standard setting is an important element of active ownership. As part of this, we develop and publish expectation documents within important areas, which we use to contribute to the improvement of standards in the market, and to form the basis of engagements with companies.

Company risk: The risk that something will happen to one or more companies in which the fund have invested causing those investments to lose value. Concentration risk: The risk that a negative event or shift in a particular sector or geography to which the fund s investments are exposed causing those investments to lose value. Systematic risk: The risk that e.g. an economic shocks or political instability in the market in which the fund invests causing all of the fund s investments to lose value. Liquidity risk: The risk that one or more of the funds investments could become hard to value, or to sell at a desired time and price. Currency risk: The risk that a negative change in a currency to which the fund is exposed causing these currency denominated investments to lose value. Sustainability risk: The risk that the occurrence of an environmental, social or governance event would exert material negative impact on the value of a given investment and result in value fluctuation.

ISIN: LU1660425346. Bloomberg ticker: DNBHCAC LX. WKN: A2DVRC

Clasificación SFDR

SFDR classification: Article 8 The fund promotes, in addition to other considerations, environmental and social aspects through its investment strategy.

Gestor(es) de fondos

Rune Sand-Holm
Lead portfolio manager
Rune holds a Master of Science in Finance from the Norwegian Business School (BI), a Certified European Financial Analyst (CEFA) and Executive MBA in Finance / Advanced portfolio management from the Norwegian School of Economics (NHH), and an ongoing Bachelor of Science in Medicine from the Norwegian University College of Health Sciences (NHFH).
Rune joined the company in April 2020 as an Analyst within the Health Sector and Portfolio Manager. Before joining the company he was a sell-side Equity Analyst at Carnegie (2012-2014) and Nordea (2014-2020).

Gestor(es) de fondos

Benedicte Kilander Bakke
Portfolio Manager
Benedicte is a doctor of dental surgery and holds an MBA from the Norwegian School of Economics and Business Administration (NHH), Norway. She is also a certified AFA-analyst from the Norwegian School of Economics and Business Administration (NHH).
After five years in DNB Corporate Banking focusing on financing of international health care companies, Bendikte joined us in 2018 as Portfolio Manager in the Health Care team. With over 20 years previous experience from the industry in different positions in international pharmacutical and smaller biotech companies, she has also been on the board of several both listed and unlisted companies in the sector.

Gestor(es) de fondos

Anesa Mulabecirovic Sahnoun
Portfolio Manager
Anesa holds a PhD in Medicine from King's College London and the University of Bergen, as well as an Executive MBA from the Norwegian School of Economics, NUS and Bocconi. She has published more than 10 scientific articles and received the Young Investigator Award for her research.
Anesa is a trained medical doctor with more than 15 years of clinical experience from Norwegian and international hospitals. Anesa joined DNB Asset Management in 2021 and is a portfolio manager in the healthcare team. Prior to DNB, she worked as an investment analyst in a specialized healthcare Venture Capital fund. She has held leadership roles in European and Norwegian medical professional organizations, including EuroSon and EFSUMB, and serves as an expert advisor to the Research Council of Norway.

Enfoques ESG

Dialogues
Yes
ESG integration
Yes
Voting
Yes
Thematic
No
Exclusions
Yes
Inclusions
No

Condiciones

Subscription fee
maximum 5%
Swing pricing
Yes
Recommended holding period
7 years
Liquidity
Daily
*Same day as valuation day. **Per annum Source: DNB Asset Management
Minimum subscription
EUR 0.00
Performance fee
None
Redemption fee
None
Management fee
1.50%
Cut-off
13:00 CET
Conditions

Clase de riesgo (SRI 1-7)

4
Summary risk indicator from 1 (lowest risk) to 7 (highest). Risk 1 is not equal to a risk-free investment. This indicator can change from time to time.

Información

Share class NAV
EUR 20.77
Asset class
Equity fund
Use of income
Accumulating
Share class inception date
10.10.2017
Industry focus
Health care
Liquidity focus
Large to medium sized companies
Fund (AuM)
EUR 133.23 million
Market focus
Across regions
Legal status
Mutual fund (UCITS)
Share class (AuM)
EUR 0.45 million
Fund index
MSCI World Health Care Index
Domicile
Luxembourg
Fund inception date
10.10.2017
Investment process
Fundamentally driven management

Datos de sostenibilidad

Carbon intensity
Index
Source: MSCI ESG Research and internal assessments. 2026 MSCI ESG Research LLC. Reproduced by permission. Based on holdings as at 30/10/2026. *MSCI World Health Care Index
Fund
ESG score (from 1 to 10)
6.61

Rendimiento acumulativo

YTDSince launchMTD5 years3 years1 year
Fund17,52 %107,67 %0,22 %37,56 %34,72 %27,09 %
Index21,41 %139,25 %-0,18 %40,7 %38,72 %26,77 %

Rentabilidad anualizada

Since launch5 years3 years1 year
Fund8,39 %6,59 %10,42 %27,11 %
Index10,1 %7,07 %11,5 %26,79 %

Año calendario

FundIndex
20254,16 %1,24 %
20244,98 %7,88 %
2023-0,83 %0,24 %
20222,93 %0,79 %
202129,89 %28,9 %
2020-8,28 %4,14 %
201921,59 %25,51 %
20189,56 %7,68 %
2017-0,24 %-1,58 %

Información de riesgo

Rel.IndexFund
Number of companies7211139
Alpha*-0,83 %n/an/a
Beta*0,99n/an/a
Information Ratio*-0,26n/an/a
Max drawdownn/a-26,64 %-25,06 %
Sharpe Ratio*n/a0,660,57
Tracking Error*4,1 %n/an/a
Volatility*n/a14,4 %14,75 %

Source: DNB Asset Management * These figures are calculated 3 years rolling based on weekly return series.

Criterios de exclusión (filtrado negativo)

Excluded companies
In addition to norm-based exclusions, the fund does not invest in companies that operate within:
Tobacco (production)
Controversial weapons
DNB's instructions for responsible investments
Cannabis for recreational use
Pornography (production)
Oil sands ≥ 30% of revenues
Coal ≥ 30% of revenues + Absolute criterion

Rendimiento

  • DNB Fund Health Care A (ACC) EUR: 20,77 (2026-11-05)
  • MSCI World Health Care Index: 239,25 (2026-11-05)

Precio

  • DNB Fund Health Care A (ACC) EUR: 20,77 (2026-11-05)

Principales subpondéraciones

  • Johnson & Johnson: -3,87 %
  • Novartis AG: -3,16 %
  • Eli Lilly & Co: -3,05 %
  • Amgen Inc: -2,74 %
  • Gilead Sciences Inc: -2,23 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Principales sobrepondéraciones

  • AstraZeneca Plc: 4,1 %
  • Roche Holding AG: 3,07 %
  • Argenx SE: 2,17 %
  • Sanofi SA: 2,12 %
  • Neurocrine Biosciences Inc: 2,1 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Principales contribuyentes

  • Dexcom Inc: 0,79 %
  • EssilorLuxottica SA: 0,63 %
  • Merck & Co Inc: 0,42 %
  • Zoetis Inc: 0,34 %
  • Abbott Laboratories: 0,34 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Principales detractores

  • Insulet Corp: -1,38 %
  • Johnson & Johnson: -0,82 %
  • Novo Nordisk A/S: -0,69 %
  • Siemens Healthineers AG: -0,61 %
  • AstraZeneca Plc: -0,55 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Principales posiciones

  • Eli Lilly & Co: 8,13 %
  • AstraZeneca Plc: 6,96 %
  • Roche Holding AG: 6,71 %
  • AbbVie Inc: 5,79 %
  • Merck & Co Inc: 5,64 %
  • UnitedHealth Group Inc: 5,05 %
  • Johnson & Johnson: 3,75 %
  • Thermo Fisher Scientific Inc: 3,44 %
  • Novo Nordisk AS: 3,34 %
  • Sanofi SA: 3,23 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Asignación por países

  • United States: 65,67 %
  • Switzerland: 9,23 %
  • United Kingdom: 6,96 %
  • Belgium: 4,65 %
  • Denmark: 4,34 %
  • France: 3,23 %
  • Germany: 2,79 %
  • Canada: 1,31 %
  • Italy: 0,65 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Asignación sectorial

  • Pharmaceut. Biotechn. & Life Sciences: 70,84 %
  • Health Care Equipment & Services: 28,01 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Asignación por divisas

  • USD: 68,4 %
  • EUR: 10,68 %
  • CHF: 9,59 %
  • GBP: 7,01 %
  • DKK: 4,34 %
  • HUF: 0 %
  • JPY: 0 %
  • SEK: 0 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Asignación por capitalización de mercado

  • > 10bn USD: 48,97 %
  • > 200bn USD: 45,47 %
  • > 5bn USD: 2,44 %
  • > 1bn USD: 1,97 %
  • Others: 0 %
  • < 1bn USD: 0 %
  • Derivative: 0 %
  • FX derivative: 0 %

Source: DNB Asset Management | Dynamic portfolio: Allocations may vary over time. Based on holdings as at 01.10.2026

Documentos

(function() { var tag = document.createElement('script'); tag.src = "https://plausible.io/js/script.outbound-links.pageview-props.tagged-events.js"; tag.defer = true; tag.setAttribute("data-domain", "dnbam.com"); var firstScriptTag = document.getElementsByTagName('script')[0]; firstScriptTag.parentNode.insertBefore(tag, firstScriptTag); })();

Este es material promocional. El rendimiento histórico no garantiza rendimientos futuros. Los rendimientos pueden ser negativos debido a caídas en los valores de mercado.